DANIEL ERNESTO
CASTELLANO GAUNA
Profesor asociado de Ciencias de la Salud
Memorial Sloan Kettering Cancer Center
Nueva York, Estados UnidosPublicaciones en colaboración con investigadores/as de Memorial Sloan Kettering Cancer Center (35)
2023
-
Durvalumab Plus Olaparib in Previously Untreated, Platinum-Ineligible Patients with Metastatic Urothelial Carcinoma: A Multicenter, Randomized, Phase II Trial (BAYOU)
Journal of Clinical Oncology, Vol. 41, Núm. 1, pp. 43-53
-
EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma
Annals of Oncology
-
Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib
European urology, Vol. 83, Núm. 3, pp. 200-209
-
Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022
European Urology
-
Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022
European Journal of Cancer
-
Results from a Phase 1b/2 Study of Ibrutinib Combination Therapy in Advanced Urothelial Carcinoma
Cancers, Vol. 15, Núm. 11
-
Rucaparib for the Treatment of Metastatic Castration-resistant Prostate Cancer Associated with a DNA Damage Repair Gene Alteration: Final Results from the Phase 2 TRITON2 Study
European Urology, Vol. 84, Núm. 3, pp. 321-330
2022
-
Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma
Cancer, Vol. 128, Núm. 11, pp. 2085-2097
-
First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial
European Urology, Vol. 81, Núm. 3, pp. 266-271
-
Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials
Clinical Cancer Research, Vol. 28, Núm. 10, pp. 2050-2060
2021
-
Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial
The Lancet Oncology, Vol. 22, Núm. 4, pp. 525-537
-
Enfortumab vedotin in previously treated advanced urothelial carcinoma
New England Journal of Medicine, Vol. 384, Núm. 12, pp. 1125-1135
-
Partial Response and Stable Disease Correlate with Positive Outcomes in Atezolizumab-treated Patients with Advanced Urinary Tract Carcinoma
European Urology Focus, Vol. 7, Núm. 5, pp. 1084-1091
-
Sequencing of PD-1/L1 Inhibitors and Carboplatin Based Chemotherapy for Cisplatin Ineligible Metastatic Urothelial Carcinoma
The Journal of urology, Vol. 205, Núm. 2, pp. 414-419
2020
-
Corrigendum to ‘EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort Under the Auspices of the EAU-ESMO Guidelines Committees’ [European Urology 77 (2020) 223–250](S0302283819307638)(10.1016/j.eururo.2019.09.035)
European Urology
-
EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort†[Formula presented]: Under the Auspices of the EAU-ESMO Guidelines Committees
European Urology, Vol. 77, Núm. 2, pp. 223-250
-
Long-term outcomes in KEYNOTE-052: Phase II study investigating first-line pembrolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer
Journal of Clinical Oncology, Vol. 38, Núm. 23, pp. 2658-2666
-
Nivolumab + ipilimumab (N+I) vs sunitinib (S) dans le traitement de première ligne du carcinome rénal avancé (aRCC) dans l’étude CheckMate 214 : suivi à 4 ans et analyse en sous-groupe des patients (pts) non néphrectomisés
Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, Vol. 30, Núm. 13, pp. 785-786
-
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: Extended 4-year follow-up of the phase III CheckMate 214 trial
ESMO Open, Vol. 5, Núm. 6
-
Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial
Cancer, Vol. 126, Núm. 18, pp. 4156-4167